{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:44:28Z","timestamp":1782603868881,"version":"3.54.5"},"reference-count":179,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004160","name":"Mazandaran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10787-020-00762-y","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T13:04:20Z","timestamp":1601643860000},"page":"1421-1438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Innate immune response in systemic autoimmune diseases: a potential target of therapy"],"prefix":"10.1007","volume":"28","author":[{"given":"Alireza","family":"Hejrati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Rafiei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Soltanshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Hosseinzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Dabiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Taghadosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeid","family":"Taghiloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davood","family":"Bashash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Khorshidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7826-1185","authenticated-orcid":false,"given":"Parisa","family":"Zafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,2]]},"reference":[{"issue":"2","key":"762_CR1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.imlet.2010.11.001","volume":"136","author":"DJ Ahern","year":"2011","unstructured":"Ahern DJ, Brennan FM (2011) The role of natural killer cells in the pathogenesis of rheumatoid arthritis: major contributors or essential homeostatic modulators? Immunol Lett 136(2):115\u2013121","journal-title":"Immunol Lett"},{"issue":"3","key":"762_CR2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/cei.13077","volume":"191","author":"M Ainola","year":"2018","unstructured":"Ainola M, Porola P, Takakubo Y, Przybyla B, Kouri V, Tolvanen T et al (2018) Activation of plasmacytoid dendritic cells by apoptotic particles\u2013mechanism for the loss of immunological tolerance in Sj\u00f6gren's syndrome. Clin Exp Immunol 191(3):301\u2013310","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"762_CR3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s10067-007-0768-x","volume":"27","author":"CM Alves","year":"2008","unstructured":"Alves CM, Marzocchi-Machado CM, Louzada-Junior P, Azzolini AEC, Polizello ACM, De Carvalho IF, Lucisano-Valim YM (2008) Superoxide anion production by neutrophils is associated with prevalent clinical manifestations in systemic lupus erythematosus. Clin Rheumatol 27(6):701\u2013708","journal-title":"Clin Rheumatol"},{"issue":"8","key":"762_CR4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41584-018-0039-z","volume":"14","author":"F Apel","year":"2018","unstructured":"Apel F, Zychlinsky A, Kenny EF (2018) The role of neutrophil extracellular traps in rheumatic diseases. Nat Rev Rheumatol 14(8):467\u2013475","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"762_CR5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ana.410190203","volume":"19","author":"K Arahata","year":"1986","unstructured":"Arahata K, Engel AG (1986) Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol 19(2):112\u2013125","journal-title":"Ann Neurol"},{"issue":"11","key":"762_CR6","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1002\/art.30568","volume":"63","author":"CM Artlett","year":"2011","unstructured":"Artlett CM, Sassi-Gaha S, Rieger JL, Boesteanu AC, Feghali-Bostwick CA, Katsikis PD (2011) The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum 63(11):3563\u20133574. https:\/\/doi.org\/10.1002\/art.30568","journal-title":"Arthritis Rheum"},{"issue":"6","key":"762_CR7","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/art.22697","volume":"56","author":"LK Assi","year":"2007","unstructured":"Assi LK, Wong SH, Ludwig A, Raza K, Gordon C, Salmon M et al (2007) Tumor necrosis factor \u03b1 activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis Rheum 56(6):1776\u20131786","journal-title":"Arthritis Rheum"},{"issue":"3","key":"762_CR8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.yexmp.2013.09.002","volume":"95","author":"B Baban","year":"2013","unstructured":"Baban B, Liu JY, Abdelsayed R, Mozaffari MS (2013) Reciprocal relation between GADD153 and Del-1 in regulation of salivary gland inflammation in Sj\u00f6gren syndrome. Exp Mol Pathol 95(3):288\u2013297","journal-title":"Exp Mol Pathol"},{"issue":"1","key":"762_CR9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/art.41062","volume":"72","author":"M Bach","year":"2020","unstructured":"Bach M, Moon J, Moore R, Pan T, Nelson JL, Lood C (2020) A neutrophil activation biomarker panel in prognosis and monitoring of patients with rheumatoid arthritis. Arthritis Rheumatol 72(1):47\u201356","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"762_CR10","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/brain\/120.6.929","volume":"120","author":"L Behrens","year":"1997","unstructured":"Behrens L, Bender A, Johnson MA, Hohlfeld R (1997) Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Brain J Neurol 120(6):929\u2013938","journal-title":"Brain J Neurol"},{"issue":"11","key":"762_CR11","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.4049\/jimmunol.161.11.5943","volume":"161","author":"L Behrens","year":"1998","unstructured":"Behrens L, Kerschensteiner M, Misgeld T, Goebels N, Wekerle H, Hohlfeld R (1998) Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J Immunol 161(11):5943\u20135951","journal-title":"J Immunol"},{"key":"762_CR12","doi-asserted-by":"crossref","unstructured":"Boisen AF, Rasmussen EB, Kragstrup TW (2019) AB0069 the downstream effect of adalimumab involves inhibition of synovial cxcl subfamily chemokine expression. Ann Rheum Dis 78:1498\u20131499","DOI":"10.1136\/annrheumdis-2019-eular.1378"},{"issue":"10","key":"762_CR13","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.2174\/138920112802273209","volume":"13","author":"M Bombardieri","year":"2012","unstructured":"Bombardieri M, Pitzalis C (2012) Ectopic lymphoid neogenesis and lymphoid chemokines in Sjogren's syndrome: at the interplay between chronic inflammation, autoimmunity and lymphomagenesis. Curr Pharm Biotechnol 13(10):1989\u20131996","journal-title":"Curr Pharm Biotechnol"},{"issue":"5","key":"762_CR14","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","volume":"72","author":"Z Brkic","year":"2013","unstructured":"Brkic Z, Maria NI, van Helden-Meeuwsen CG, van de Merwe JP, van Daele PL, Dalm VA et al (2013) Prevalence of interferon type I signature in CD14 monocytes of patients with Sj\u00f6gren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 72(5):728\u2013735","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"762_CR15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00281-013-0375-7","volume":"35","author":"C Carmona-Rivera","year":"2013","unstructured":"Carmona-Rivera C, Kaplan MJ (2013) Low-density granulocytes: a distinct class of neutrophils in systemic autoimmunity. Semin Immunopathol 35(4):455\u2013463","journal-title":"Semin Immunopathol"},{"issue":"10","key":"762_CR16","doi-asserted-by":"crossref","first-page":"eaag3358","DOI":"10.1126\/sciimmunol.aag3358","volume":"2","author":"C Carmona-Rivera","year":"2017","unstructured":"Carmona-Rivera C, Carlucci PM, Moore E, Lingampalli N, Uchtenhagen H, James E et al (2017) Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis. Sci Immunol 2(10):eaag3358","journal-title":"Sci Immunol"},{"issue":"5","key":"762_CR17","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/rheumatology\/41.5.484%JRheumatology","volume":"41","author":"AI Catrina","year":"2002","unstructured":"Catrina AI, Lampa J, Ernestam S, Af Klint E, Bratt J, Klareskog L, Ulfgren AK (2002) Anti-tumour necrosis factor (TNF)-\u03b1 therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology 41(5):484\u2013489. https:\/\/doi.org\/10.1093\/rheumatology\/41.5.484%JRheumatology","journal-title":"Rheumatology"},{"issue":"3","key":"762_CR18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1172\/JCI127101","volume":"129","author":"Y Chaichian","year":"2019","unstructured":"Chaichian Y, Wallace DJ, Weisman MH (2019) A promising approach to targeting type 1 IFN in systemic lupus erythematosus. J Clin Invest 129(3):958\u2013961","journal-title":"J Clin Invest"},{"issue":"108","key":"762_CR19","first-page":"43","volume":"20","author":"SA Chalmers","year":"2015","unstructured":"Chalmers SA, Chitu V, Ramanujam M, Putterman C (2015) Therapeutic targeting of macrophages in lupus nephritis. Discov Med 20(108):43\u201349","journal-title":"Discov Med"},{"issue":"6","key":"762_CR20","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nm.2159","volume":"16","author":"N Charles","year":"2010","unstructured":"Charles N, Hardwick D, Daugas E, Illei GG, Rivera J (2010) Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med 16(6):701","journal-title":"Nat Med"},{"key":"762_CR21","first-page":"206731","volume":"2015","author":"J Chen","year":"2015","unstructured":"Chen J, Wu M, Wang J, Li X (2015) Immunoregulation of NKT cells in systemic lupus erythematosus. J Immunol Res 2015:206731","journal-title":"J Immunol Res"},{"key":"762_CR22","first-page":"8549329","volume":"2018","author":"W Chen","year":"2018","unstructured":"Chen W, Wang Q, Ke Y, Lin J (2018) Neutrophil function in an inflammatory milieu of rheumatoid arthritis. J Immunol Res 2018:8549329","journal-title":"J Immunol Res"},{"issue":"6","key":"762_CR23","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/rheumatology\/keq457","volume":"50","author":"Y-N Cho","year":"2011","unstructured":"Cho Y-N, Kee S-J, Lee S-J, Seo S-R, Kim T-J, Lee S-S et al (2011) Numerical and functional deficiencies of natural killer T cells in systemic lupus erythematosus: their deficiency related to disease activity. Rheumatology 50(6):1054\u20131063","journal-title":"Rheumatology"},{"key":"762_CR24","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1017\/erm.2013.10","volume":"15","author":"M Ciechomska","year":"2013","unstructured":"Ciechomska M, Cant R, Finnigan J, van Laar JM, O'Reilly S (2013) Role of toll-like receptors in systemic sclerosis. Expert Rev Mol Med 15:e9","journal-title":"Expert Rev Mol Med"},{"issue":"8","key":"762_CR25","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1136\/annrheumdis-2012-201958","volume":"72","author":"M Ciechomska","year":"2013","unstructured":"Ciechomska M, Huigens CA, H\u00fcgle T, Stanly T, Gessner A, Griffiths B et al (2013b) Toll-like receptor-mediated, enhanced production of profibrotic TIMP-1 in monocytes from patients with systemic sclerosis: role of serum factors. Ann Rheum Dis 72(8):1382\u20131389. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201958","journal-title":"Ann Rheum Dis"},{"key":"762_CR26","first-page":"347","volume":"37","author":"C Croia","year":"2019","unstructured":"Croia C, Bursi R, Sutera D, Petrelli F, Alunno A, Puxeddu I (2019) One year in review 2019: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 37:347\u2013357","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"762_CR27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/rheumatology\/40.1.62","volume":"40","author":"G Cunnane","year":"2001","unstructured":"Cunnane G, Madigan A, Murphy E, FitzGerald O, Bresnihan BJR (2001) The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology 40(1):62\u201369","journal-title":"Rheumatology"},{"issue":"21","key":"762_CR28","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","volume":"325","author":"MC Dalakas","year":"1991","unstructured":"Dalakas MC (1991) Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 325(21):1487\u20131498","journal-title":"N Engl J Med"},{"issue":"9388","key":"762_CR29","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362(9388):971\u2013982. https:\/\/doi.org\/10.1016\/S0140-6736(03)14368-1","journal-title":"Lancet"},{"key":"762_CR30","doi-asserted-by":"crossref","first-page":"v64","DOI":"10.1007\/s00415-006-5010-2","volume":"253","author":"D Pongratz","year":"2006","unstructured":"Pongratz D (2006) Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis). J Neurol 253:v64\u2013v65","journal-title":"J Neurol"},{"issue":"12","key":"762_CR31","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1212\/WNL.58.12.1779","volume":"58","author":"JL De Bleecker","year":"2002","unstructured":"De Bleecker JL, De Paepe B, Vanwalleghem IE, Schr\u00f6der JM (2002) Differential expression of chemokines in inflammatory myopathies. Neurology 58(12):1779\u20131785","journal-title":"Neurology"},{"issue":"95","key":"762_CR32","first-page":"247","volume":"17","author":"B Dema","year":"2014","unstructured":"Dema B, Charles N (2014) Advances in mechanisms of systemic lupus erythematosus. Discov Med 17(95):247\u2013255","journal-title":"Discov Med"},{"issue":"1","key":"762_CR33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0714.2008.00700.x","volume":"38","author":"US Deshmukh","year":"2009","unstructured":"Deshmukh US, Nandula SR, Thimmalapura PR, Scindia YM, Bagavant H (2009) Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function. J Oral Pathol Med 38(1):42\u201347","journal-title":"J Oral Pathol Med"},{"key":"762_CR34","doi-asserted-by":"crossref","first-page":"101339","DOI":"10.1016\/j.smim.2019.101339","volume":"45","author":"DJ Dijkstra","year":"2019","unstructured":"Dijkstra DJ, Joeloemsingh JV, Bajema IM, Trouw LA (2019) Complement activation and regulation in rheumatic disease. Semin Immunol 45:101339","journal-title":"Semin Immunol"},{"key":"762_CR35","first-page":"575","volume":"76","author":"T D\u00f6rner","year":"2017","unstructured":"D\u00f6rner T, Weinblatt M, Van Beneden K, Dombrecht E, De Beuf K, Schoen P, Zeldin RK (2017) FRI0239 Results of a phase 2b study of vobarilizumab, an anti-interleukin-6 receptor nanobody, as monotherapy in patients with moderate to severe rheumatoid arthritis. Ann Rheum Dis 76:575","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"762_CR36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11926-017-0630-3","volume":"19","author":"C Dowson","year":"2017","unstructured":"Dowson C, Simpson N, Duffy L, O'Reilly S (2017) Innate immunity in systemic sclerosis. Curr Rheumatol Rep 19(1):2. https:\/\/doi.org\/10.1007\/s11926-017-0630-3","journal-title":"Curr Rheumatol Rep"},{"key":"762_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/ITT.S89795","volume":"5","author":"L Duffy","year":"2016","unstructured":"Duffy L, O'Reilly SC (2016) Toll-like receptors in the pathogenesis of autoimmune diseases: recent and emerging translational developments. ImmunoTargets Therapy 5:69\u201380. https:\/\/doi.org\/10.2147\/ITT.S89795","journal-title":"ImmunoTargets Therapy"},{"issue":"9","key":"762_CR38","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1002\/art.22860","volume":"56","author":"M-L Eloranta","year":"2007","unstructured":"Eloranta M-L, Barbasso Helmers S, Ulfgren A-K, R\u00f6nnblom L, Alm GV, Lundberg IE (2007) A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52\/anti-Ro 60 autoantibodies. Arthritis Rheum 56(9):3112\u20133124. https:\/\/doi.org\/10.1002\/art.22860","journal-title":"Arthritis Rheum"},{"issue":"9","key":"762_CR39","doi-asserted-by":"crossref","first-page":"e0162316","DOI":"10.1371\/journal.pone.0162316","volume":"11","author":"GP Eng","year":"2016","unstructured":"Eng GP, Bouchelouche P, Bartels EM, Bliddal H, Bendtzen K, Stoltenberg MJPO (2016) Anti-drug antibodies, drug levels, interleukin-6 and soluble TNF receptors in rheumatoid arthritis patients during the first 6 months of treatment with adalimumab or infliximab: a descriptive cohort study. PLoS One 11(9):e0162316","journal-title":"PLoS One"},{"key":"762_CR40","doi-asserted-by":"crossref","first-page":"584303","DOI":"10.1155\/2013\/584303","volume":"2013","author":"L Estrada-Capetillo","year":"2013","unstructured":"Estrada-Capetillo L, Hern\u00e1ndez-Castro B, Monsiv\u00e1is-Urenda A, Alvarez-Quiroga C, Layseca-Espinosa E, Abud-Mendoza C et al (2013) Induction of Th17 lymphocytes and Treg cells by monocyte-derived dendritic cells in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Dev Immunol 2013:584303","journal-title":"Clin Dev Immunol"},{"issue":"8","key":"762_CR41","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1002\/art.39655","volume":"68","author":"F Fang","year":"2016","unstructured":"Fang F, Marangoni RG, Zhou X, Yang Y, Ye B, Shangguang A et al (2016) Toll-like receptor 9 signaling is augmented in systemic sclerosis and elicits transforming growth factor beta-dependent fibroblast activation. Arthritis Rheumatol 68(8):1989\u20132002. https:\/\/doi.org\/10.1002\/art.39655","journal-title":"Arthritis Rheumatol"},{"key":"762_CR42","unstructured":"FDA (2008) Certolizumab pegol label information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/125160s000lbl.pdf. Accessed 18 Apr 2008"},{"issue":"8","key":"762_CR43","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.autrev.2018.02.011","volume":"17","author":"R Felten","year":"2018","unstructured":"Felten R, Dervovic E, Chasset F, Gottenberg J-E, Sibilia J, Scher F, Arnaud LJAR (2018) The 2018 pipeline of targeted therapies under clinical development for systemic lupus erythematosus: a systematic review of trials. Autoimmunity Rev 17(8):781\u2013790","journal-title":"Autoimmunity Rev"},{"issue":"4","key":"762_CR44","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jbspin.2018.09.004","volume":"86","author":"R Felten","year":"2019","unstructured":"Felten R, Scher F, Sibilia J, Chasset F, Arnaud LJJBS (2019) Advances in the treatment of systemic lupus erythematosus: from back to the future, to the future and beyond. Joint Bone Spine 86(4):429\u2013436","journal-title":"Joint Bone Spine"},{"issue":"4","key":"762_CR45","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/ar4232","volume":"15","author":"LA Fogel","year":"2013","unstructured":"Fogel LA, Yokoyama WM, French AR (2013) Natural killer cells in human autoimmune disorders. Arthritis Res Ther 15(4):216","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"762_CR46","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaci.2017.07.041","volume":"142","author":"O Fogel","year":"2018","unstructured":"Fogel O, Rivi\u00e8re E, Seror R, Nocturne G, Boudaoud S, Ly B et al (2018) Role of the IL-12\/IL-35 balance in patients with Sj\u00f6gren syndrome. J Allergy Clin Immunol 142(1):258\u2013268","journal-title":"J Allergy Clin Immunol"},{"key":"762_CR47","unstructured":"Food and Drug Administration (2009) Golimumab pegol label information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125289s000lbl.pdf. Accessed 20 Mar 2009"},{"issue":"1","key":"762_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1740-2557-5-1","volume":"5","author":"M Fridkis-Hareli","year":"2008","unstructured":"Fridkis-Hareli M (2008) Immunogenetic mechanisms for the coexistence of organ-specific and systemic autoimmune diseases. J Autoimmune Dis 5(1):1","journal-title":"J Autoimmune Dis"},{"issue":"6","key":"762_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/rheumatology\/kez387","volume":"58","author":"S Frizinsky","year":"2019","unstructured":"Frizinsky S, Haj-Yahia S, Maayan DM, Lifshitz Y, Maoz-Segal R, Offengenden I et al (2019) The innate immune perspective of autoimmune and autoinflammatory conditions. Rheumatology 58(6):1\u20138","journal-title":"Rheumatology"},{"issue":"2","key":"762_CR50","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/14728214.2019.1634052","volume":"24","author":"S Gandolfo","year":"2019","unstructured":"Gandolfo S, De Vita SJE (2019) Emerging drugs for primary Sj\u00f6gren\u2019s syndrome. Expert Opin Emerg Drugs 24(2):121\u2013132","journal-title":"Expert Opin Emerg Drugs"},{"key":"762_CR51","unstructured":"Gillooly K, Zhang Y, Yang X, Zupa-Fernandez A, Cheng L, Strnad J et al (2016) BMS-986165 is a highly potent and selective allosteric inhibitor of Tyk2, blocks IL-12, IL-23 and type I interferon signaling and provides for robust efficacy in preclinical models of systemic lupus erythematosus and inflammatory bowel disease [abstract]. Arthritis Rheumatol\u00a0 68 (suppl 10)"},{"issue":"10","key":"762_CR52","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/ard.50.10.685","volume":"50","author":"B Gudbj\u00f6rnsson","year":"1991","unstructured":"Gudbj\u00f6rnsson B, Feltelius N, H\u00e4llgren R, Venge P (1991) Neutrophil function in patients with primary Sj\u00f6gren's syndrome: relation to infection propensity. Ann Rheum Dis 50(10):685\u2013690","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"762_CR53","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nrneph.2016.71","volume":"12","author":"S Gupta","year":"2016","unstructured":"Gupta S, Kaplan MJ (2016) The role of neutrophils and NETosis in autoimmune and renal diseases. Nat Rev Nephrol 12(7):402","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"762_CR54","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrrheum.2011.222","volume":"8","author":"HE Harris","year":"2012","unstructured":"Harris HE, Andersson U, Pisetsky DS (2012) HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 8(4):195\u2013202. https:\/\/doi.org\/10.1038\/nrrheum.2011.222","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"762_CR55","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/rheumatology\/ker019","volume":"50","author":"G Hern\u00e1ndez-Molina","year":"2011","unstructured":"Hern\u00e1ndez-Molina G, Michel-Peregrina M, Hern\u00e1ndez-Ram\u00edrez DF, S\u00e1nchez-Guerrero J, Llorente L (2011) Chemokine saliva levels in patients with primary Sj\u00f6gren\u2019s syndrome, associated Sj\u00f6gren\u2019s syndrome, pre-clinical Sj\u00f6gren\u2019s syndrome and systemic autoimmune diseases. Rheumatology 50(7):1288\u20131292","journal-title":"Rheumatology"},{"key":"762_CR56","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3389\/fimmu.2019.00772","volume":"10","author":"AA Herrada","year":"2019","unstructured":"Herrada AA, Escobedo N, Iruretagoyena M, Valenzuela RA, Burgos PI, Cuitino L, Llanos C (2019) Innate immune cells' contribution to systemic lupus erythematosus. Front Immunol 10:772","journal-title":"Front Immunol"},{"issue":"6","key":"762_CR57","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/art.30313","volume":"63","author":"B Hervier","year":"2011","unstructured":"Hervier B, Beziat V, Haroche J, Mathian A, Lebon P, Ghillani-Dalbin P et al (2011) Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-\u03b3 production in patients with active disease. Arthritis Rheum 63(6):1698\u20131706","journal-title":"Arthritis Rheum"},{"issue":"4","key":"762_CR58","doi-asserted-by":"publisher","first-page":"R128","DOI":"10.1186\/ar3066","volume":"12","author":"N Higashi-Kuwata","year":"2010","unstructured":"Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC et al (2010) Characterization of monocyte\/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther 12(4):R128\u2013R128. https:\/\/doi.org\/10.1186\/ar3066","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"762_CR59","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nchembio.1393","volume":"9","author":"AL Hilchie","year":"2013","unstructured":"Hilchie AL, Wuerth K, Hancock RE (2013) Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat Chem Biol 9(12):761","journal-title":"Nat Chem Biol"},{"issue":"9250","key":"762_CR60","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","volume":"357","author":"CL Hill","year":"2001","unstructured":"Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A et al (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357(9250):96\u2013100","journal-title":"Lancet"},{"key":"762_CR61","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3389\/fimmu.2019.02096","volume":"10","author":"MR Hillen","year":"2019","unstructured":"Hillen MR, Pandit A, Blokland SL, Hartgring SA, Bekker CP, van der Heijden EH et al (2019) Plasmacytoid DCs from patients with Sj\u00f6gren's syndrome are transcriptionally primed for enhanced pro-inflammatory cytokine production. Front Immunol 10:2096","journal-title":"Front Immunol"},{"issue":"4","key":"762_CR62","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/j.lpm.2010.10.035","volume":"40","author":"D Hilton-Jones","year":"2011","unstructured":"Hilton-Jones D (2011) Observations on the classification of the inflammatory myopathies. Presse Med 40(4):e199\u2013e208","journal-title":"Presse Med"},{"issue":"6","key":"762_CR63","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.4049\/jimmunol.1000569","volume":"186","author":"Z Huang","year":"2011","unstructured":"Huang Z, Fu B, Zheng SG, Li X, Sun R, Tian Z, Wei H (2011) Involvement of CD226+ NK cells in immunopathogenesis of systemic lupus erythematosus. J Immunol 186(6):3421\u20133431","journal-title":"J Immunol"},{"key":"762_CR64","first-page":"w13999","volume":"144","author":"T H\u00fcgle","year":"2014","unstructured":"H\u00fcgle T (2014) Beyond allergy: the role of mast cells in fibrosis. Swiss Med Weekly 144:w13999","journal-title":"Swiss Med Weekly"},{"issue":"9","key":"762_CR65","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1136\/annrheumdis-2011-200809","volume":"71","author":"T Hugle","year":"2012","unstructured":"Hugle T, White K, van Laar JM (2012) Cell-to-cell contact of activated mast cells with fibroblasts and lymphocytes in systemic sclerosis. Ann Rheum Dis 71(9):1582. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200809","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"762_CR66","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","volume":"73","author":"TW Huizinga","year":"2014","unstructured":"Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S et al (2014) Sarilumab, a fully human monoclonal antibody against IL-6R\u03b1 in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheumatic Diseases 73(9):1626\u20131634","journal-title":"Ann Rheumatic Diseases"},{"issue":"5","key":"762_CR67","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16(5):448\u2013457","journal-title":"Nat Immunol"},{"issue":"2","key":"762_CR68","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1136\/jcp.2004.019224","volume":"58","author":"MR Hussein","year":"2005","unstructured":"Hussein MR, Hassan HI, Hofny ER, Elkholy M, Fatehy NA, Abd Elmoniem AE et al (2005) Alterations of mononuclear inflammatory cells, CD4\/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol 58(2):178\u2013184. https:\/\/doi.org\/10.1136\/jcp.2004.019224","journal-title":"J Clin Pathol"},{"issue":"6","key":"762_CR69","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/cells8060561","volume":"8","author":"Y Ikari","year":"2019","unstructured":"Ikari Y, Isozaki T, Tsubokura Y, Kasama TJC (2019) Peficitinib inhibits the chemotactic activity of monocytes via proinflammatory cytokine production in rheumatoid arthritis fibroblast-like synoviocytes. Cells 8(6):561","journal-title":"Cells"},{"issue":"1","key":"762_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-019-3589-8","volume":"20","author":"N Iwamoto","year":"2019","unstructured":"Iwamoto N, Sato S, Sumiyoshi R, Chiba K, Miyamoto N, Arinaga K et al (2019) Comparative study of the inhibitory effect on bone erosion progression with denosumab treatment and conventional treatment in rheumatoid arthritis patients: study protocol for an open-label randomized controlled trial by HR-pQCT. Trials 20(1):1\u20138","journal-title":"Trials"},{"issue":"5","key":"762_CR71","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.lab.2006.01.001","volume":"147","author":"Y Izumi","year":"2006","unstructured":"Izumi Y, Ida H, Huang M, Iwanaga N, Tanaka F, Aratake K et al (2006) Characterization of peripheral natural killer cells in primary Sj\u00f6gren\u2019s syndrome: impaired NK cell activity and low NK cell number. J Lab Clin Med 147(5):242\u2013249","journal-title":"J Lab Clin Med"},{"key":"762_CR72","doi-asserted-by":"crossref","first-page":"109704","DOI":"10.1016\/j.biopha.2019.109704","volume":"122","author":"H Jiang","year":"2020","unstructured":"Jiang H, Gao H, Wang Q, Wang M, Wu BJB (2020) Molecular mechanisms and clinical application of Iguratimod: a review. Biomed Pharmacother 122:109704","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"762_CR73","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.4049\/jimmunol.1302005","volume":"191","author":"JM Kahlenberg","year":"2013","unstructured":"Kahlenberg JM, Kaplan MJ (2013) Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol 191(10):4895\u20134901","journal-title":"J Immunol"},{"issue":"3","key":"762_CR74","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/rheumatology\/kex426","volume":"57","author":"T Karonitsch","year":"2018","unstructured":"Karonitsch T, Beckmann D, Dalwigk K, Niederreiter B, Studenic P, Byrne RA et al (2018) Targeted inhibition of Janus kinases abates interfon gamma-induced invasive behaviour of fibroblast-like synoviocytes. Rheumatology 57(3):572\u2013577","journal-title":"Rheumatology"},{"key":"762_CR75","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fimmu.2011.00052","volume":"2","author":"A Kennedy","year":"2011","unstructured":"Kennedy A, Fearon U, Veale DJ, Godson C (2011) Macrophages in synovial inflammation. Front Immunol 2:52","journal-title":"Front Immunol"},{"issue":"178","key":"762_CR76","doi-asserted-by":"crossref","first-page":"178ra140","DOI":"10.1126\/scitranslmed.3005580","volume":"5","author":"R Khandpur","year":"2013","unstructured":"Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, Knight JS et al (2013) NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med 5(178):178ra140","journal-title":"Sci Transl Med"},{"issue":"3","key":"762_CR77","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/jid.2009.302","volume":"130","author":"HJ Kim","year":"2010","unstructured":"Kim HJ, Song SB, Choi JM, Kim KM, Cho BK, Cho DH, Park HJ (2010) IL-18 downregulates collagen production in human dermal fibroblasts via the ERK pathway. J Invest Dermatol 130(3):706\u2013715. https:\/\/doi.org\/10.1038\/jid.2009.302","journal-title":"J Invest Dermatol"},{"key":"762_CR78","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clim.2017.04.003","volume":"182","author":"J Kiripolsky","year":"2017","unstructured":"Kiripolsky J, McCabe LG, Kramer JM (2017) Innate immunity in Sj\u00f6gren's syndrome. Clin Immunol 182:4\u201313","journal-title":"Clin Immunol"},{"issue":"2","key":"762_CR79","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40259-020-00405-2","volume":"34","author":"K Klavdianou","year":"2020","unstructured":"Klavdianou K, Lazarini A, Fanouriakis AJB (2020) Targeted biologic therapy for systemic lupus erythematosus: emerging pathways and drug pipeline. BioDrugs 34(2):133\u2013147","journal-title":"BioDrugs"},{"issue":"2","key":"762_CR80","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1600-0404.1996.tb07039.x","volume":"94","author":"T Kumamoto","year":"1996","unstructured":"Kumamoto T, Ueyama H, Fujimoto S, Nagao S, Tsuda T (1996) Clinicopathologic characteristics of polymyositis patients with numerous tissue eosinophils. Acta Neurol Scand 94(2):110\u2013114. https:\/\/doi.org\/10.1111\/j.1600-0404.1996.tb07039.x","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"762_CR81","doi-asserted-by":"crossref","first-page":"390","DOI":"10.5114\/ceji.2017.72807","volume":"42","author":"W Kurowska","year":"2017","unstructured":"Kurowska W, Kuca-Warnawin EH, Radzikowska A, Ma\u015bli\u0144ski W (2017) The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis. Central-Eur J Immunol 42(4):390","journal-title":"Central-Eur J Immunol"},{"issue":"4","key":"762_CR82","doi-asserted-by":"crossref","first-page":"275","DOI":"10.14348\/molcells.2014.2374","volume":"37","author":"AC Labonte","year":"2014","unstructured":"Labonte AC, Tosello-Trampont A-C, Hahn YS (2014) The role of macrophage polarization in infectious and inflammatory diseases. Mol Cells 37(4):275","journal-title":"Mol Cells"},{"issue":"73","key":"762_CR83","doi-asserted-by":"crossref","first-page":"73ra19","DOI":"10.1126\/scitranslmed.3001180","volume":"3","author":"R Lande","year":"2011","unstructured":"Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J et al (2011) Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA\u2013peptide complexes in systemic lupus erythematosus. Sci Transl Med 3(73):73ra19","journal-title":"Sci Transl Med"},{"issue":"4","key":"762_CR84","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2353\/ajpath.2008.070703","volume":"172","author":"MC Lebre","year":"2008","unstructured":"Lebre MC, Jongbloed SL, Tas SW, Smeets TJ, McInnes IB, Tak PP (2008) Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP-dendritic cells with distinct cytokine profiles. Am J Pathol 172(4):940\u2013950","journal-title":"Am J Pathol"},{"issue":"4","key":"762_CR85","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1159\/000430251","volume":"37","author":"F Li","year":"2015","unstructured":"Li F, Yang Y, Zhu X, Huang L, Xu J (2015) Macrophage polarization modulates development of systemic lupus erythematosus. Cell Physiol Biochem 37(4):1279\u20131288","journal-title":"Cell Physiol Biochem"},{"issue":"10","key":"762_CR86","doi-asserted-by":"crossref","first-page":"e0186223","DOI":"10.1371\/journal.pone.0186223","volume":"12","author":"S-J Lin","year":"2017","unstructured":"Lin S-J, Kuo M-L, Hsiao H-S, Lee P-T, Chen J-Y, Huang J-L (2017) Activating and inhibitory receptors on natural killer cells in patients with systemic lupus erythematosis-regulation with interleukin-15. PLoS One 12(10):e0186223","journal-title":"PLoS One"},{"issue":"4","key":"762_CR87","doi-asserted-by":"publisher","first-page":"e1045","DOI":"10.1002\/cti2.1045","volume":"8","author":"E Lin","year":"2019","unstructured":"Lin E, Vincent FB, Sahhar J, Ngian G-S, Kandane-Rathnayake R, Mende R et al (2019) Analysis of serum interleukin(IL)-1\u03b1, IL-1\u03b2 and IL-18 in patients with systemic sclerosis. Clin Transl Immunol 8(4):e1045. https:\/\/doi.org\/10.1002\/cti2.1045","journal-title":"Clin Transl Immunol"},{"issue":"6","key":"762_CR88","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/PAT.0b013e3283580388","volume":"44","author":"S Lisi","year":"2012","unstructured":"Lisi S, Sisto M, Lofrumento DD, D\u2019Amore M (2012) Altered IkB\u03b1 expression promotes NF-kB activation in monocytes from primary Sj\u00f6gren\u2019s syndrome patients. Pathology 44(6):557\u2013561","journal-title":"Pathology"},{"key":"762_CR89","doi-asserted-by":"publisher","first-page":"148293","DOI":"10.1155\/2014\/148293","volume":"2014","author":"JM L\u00f3pez-Cacho","year":"2014","unstructured":"L\u00f3pez-Cacho JM, Gallardo S, Posada M, Aguerri M, Calzada D, Mayayo T et al (2014) Association of immunological cell profiles with specific clinical phenotypes of scleroderma disease. Biomed Res Int 2014:148293. https:\/\/doi.org\/10.1155\/2014\/148293","journal-title":"Biomed Res Int"},{"issue":"3","key":"762_CR90","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/ar3318","volume":"13","author":"HZ Low","year":"2011","unstructured":"Low HZ, Witte T (2011) Aspects of innate immunity in Sj\u00f6gren's syndrome. Arthritis Res Ther 13(3):218","journal-title":"Arthritis Res Ther"},{"key":"762_CR91","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaut.2016.12.003","volume":"78","author":"X Lu","year":"2017","unstructured":"Lu X, Tang Q, Lindh M, Dastmalchi M, Alexanderson H, Popovic Silwerfeldt K et al (2017) The host defense peptide LL-37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis. J Autoimmun 78:46\u201356. https:\/\/doi.org\/10.1016\/j.jaut.2016.12.003","journal-title":"J Autoimmun"},{"issue":"7","key":"762_CR92","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3390\/cells8070700","volume":"8","author":"B Lucchino","year":"2019","unstructured":"Lucchino B, Spinelli FR, Iannuccelli C, Guzzo MP, Conti F, Franco MD (2019) Mucosa-environment interactions in the pathogenesis of rheumatoid arthritis. Cells 8(7):700","journal-title":"Cells"},{"key":"762_CR93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2019.06.009","volume":"207","author":"C Ma","year":"2019","unstructured":"Ma C, Xia Y, Yang Q, Zhao Y (2019) The contribution of macrophages to systemic lupus erythematosus. Clin Immunol 207:1\u20139","journal-title":"Clin Immunol"},{"key":"762_CR94","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3389\/fimmu.2019.01140","volume":"10","author":"W-T Ma","year":"2019","unstructured":"Ma W-T, Gao F, Gu K, Chen D-K (2019) The role of monocytes and macrophages in autoimmune diseases: a comprehensive review. Front Immunol 10:1140","journal-title":"Front Immunol"},{"issue":"4","key":"762_CR95","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/imm.12504","volume":"146","author":"JP Mackern-Oberti","year":"2015","unstructured":"Mackern-Oberti JP, Llanos C, Riedel CA, Bueno SM, Kalergis AM (2015) Contribution of dendritic cells to the autoimmune pathology of systemic lupus erythematosus. Immunology 146(4):497\u2013507","journal-title":"Immunology"},{"issue":"6","key":"762_CR96","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/acr.21610","volume":"64","author":"AS Malladi","year":"2012","unstructured":"Malladi AS, Sack KE, Shiboski SC, Shiboski CH, Baer AN, Banushree R et al (2012) Primary Sj\u00f6gren's syndrome as a systemic disease: a study of participants enrolled in an international Sj\u00f6gren's syndrome registry. Arthritis Care Res 64(6):911\u2013918","journal-title":"Arthritis Care Res"},{"issue":"3","key":"762_CR97","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12016-007-8007-4","volume":"32","author":"MN Manoussakis","year":"2007","unstructured":"Manoussakis MN, Kapsogeorgou EK (2007) The role of epithelial cells in the pathogenesis of Sj\u00f6gren\u2019s syndrome. Clin Rev Allergy Immunol 32(3):225\u2013230","journal-title":"Clin Rev Allergy Immunol"},{"issue":"12","key":"762_CR98","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","volume":"25","author":"A Mantovani","year":"2004","unstructured":"Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25(12):677\u2013686","journal-title":"Trends Immunol"},{"issue":"3","key":"762_CR99","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2353\/ajpath.2007.070166","volume":"171","author":"MM Markiewski","year":"2007","unstructured":"Markiewski MM, Lambris JD (2007) The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 171(3):715\u2013727","journal-title":"Am J Pathol"},{"issue":"2","key":"762_CR100","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","volume":"10","author":"F Martinon","year":"2002","unstructured":"Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-\u03b2. Mol Cell 10(2):417\u2013426","journal-title":"Mol Cell"},{"key":"762_CR101","doi-asserted-by":"crossref","first-page":"A28","DOI":"10.1136\/annrheumdis-2018-213340","volume":"78","author":"V Marzaioli","year":"2019","unstructured":"Marzaioli V, Canavan M, Floudas A, Wade S, Low C, Veale D, Fearon U (2019) P067 Tofacitinib impairs monocyte-derived dendritic cell differentiation in rheumatoid arthritisand psoriatic arthritis. Ann Rheum Dis 78:A28","journal-title":"Ann Rheum Dis"},{"key":"762_CR102","doi-asserted-by":"crossref","first-page":"102364","DOI":"10.1016\/j.jaut.2019.102364","volume":"110","author":"CP Mavragani","year":"2019","unstructured":"Mavragani CP, Moutsopoulos HMJJA (2019) Sj\u00f6gren's syndrome: old and new therapeutic targets. J Autoimmun 110:102364","journal-title":"J Autoimmun"},{"issue":"1","key":"762_CR103","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3904\/kjim.2019.271","volume":"35","author":"HK Min","year":"2020","unstructured":"Min HK, Kim K-W, Lee S-H, Kim H-R (2020) Roles of mast cells in rheumatoid arthritis. Korean J Internal Med 35(1):12","journal-title":"Korean J Internal Med"},{"issue":"2","key":"762_CR104","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/cei.12970","volume":"189","author":"TS Mitchell","year":"2017","unstructured":"Mitchell TS, Moots RJ, Wright HL (2017) Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production. Clin Exp Immunol 189(2):250\u2013258","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"762_CR105","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/art.23447","volume":"58","author":"H Mitoma","year":"2008","unstructured":"Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A (2008) Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor \u03b1-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 58(5):1248\u20131257","journal-title":"Arthritis Rheum"},{"issue":"2","key":"762_CR106","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jcph.1513","volume":"60","author":"MEF Mohamed","year":"2020","unstructured":"Mohamed MEF, Beck D, Camp HS, Othman AAJ (2020) Preferential inhibition of JAK1 relative to JAK3 by upadacitinib: exposure-response analyses of ex vivo data from 2 phase 1 clinical trials and comparison to tofacitinib. J Clin Pharmacol 60(2):188\u2013197","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"762_CR107","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/1756-185X.12532","volume":"18","author":"MY Mok","year":"2015","unstructured":"Mok MY (2015) Tolerogenic dendritic cells: role and therapeutic implications in systemic lupus erythematosus. Int J Rheumatic Dis 18(2):250\u2013259","journal-title":"Int J Rheumatic Dis"},{"issue":"11","key":"762_CR108","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","volume":"13","author":"A Nesbitt","year":"2007","unstructured":"Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R et al (2007) Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor \u03b1 agents. Inflamm Bowel Dis 13(11):1323\u20131332","journal-title":"Inflamm Bowel Dis"},{"key":"762_CR109","doi-asserted-by":"crossref","first-page":"S444","DOI":"10.14309\/00000434-200910003-01198","volume":"104","author":"A Nesbitt","year":"2009","unstructured":"Nesbitt A, Lamour S, Bracher MJ (2009) PEG component of certolizumab pegol inhibits stimulated mast cell degranulation. Am J Gastroenterol 104:S444","journal-title":"Am J Gastroenterol"},{"key":"762_CR110","unstructured":"NIH (2020) Efficacy and safety study of p144 to treat skin fibrosis in systemic sclerosis. https:\/\/ClinicalTrials.gov\/show\/NCT00574613. Accessed 11 Feb 2013"},{"key":"762_CR111","unstructured":"NIH (2020) Fresolimumab in systemic sclerosis. https:\/\/ClinicalTrials.gov\/show\/NCT01284322. Accessed 16 July 2014"},{"key":"762_CR112","unstructured":"NIH (2020) Imatinib mesylate (Gleevec) in the treatment of systemic sclerosis. https:\/\/ClinicalTrials.gov\/show\/NCT00555581. Accessed 6 Feb 2018"},{"key":"762_CR113","unstructured":"NIH (2020) Nilotinib in the treatment of systemic sclerosis. https:\/\/ClinicalTrials.gov\/show\/NCT01166139. Accessed 4 Oct 2017"},{"key":"762_CR114","unstructured":"NIH (2020) A phase 1 study of MEDI7734 in type I interferon-mediated autoimmune diseases. https:\/\/ClinicalTrials.gov\/show\/NCT02780674. Accessed 21 Dec 2018"},{"key":"762_CR115","unstructured":"NIH (2020) Proof of biological activity of SAR100842 in systemic sclerosis. https:\/\/ClinicalTrials.gov\/show\/NCT01651143. Accessed 25 Mar 2016"},{"key":"762_CR116","unstructured":"NIH (2020) Safety evaluation of dasatinib in subjects with scleroderma pulmonary fibrosis. https:\/\/ClinicalTrials.gov\/show\/NCT00764309. Accessed 29 Feb 2012"},{"key":"762_CR117","unstructured":"NIH (2020) Safety, tolerability, and pharmacokinetics of CAT-192 (human anti-TGF-beta1 monoclonal antibody) in patients with early stage diffuse systemic sclerosis. https:\/\/ClinicalTrials.gov\/show\/NCT00043706. Accessed 5 Mar 2015"},{"key":"762_CR118","unstructured":"NIH (2020) Study of iguratimod in Sj\u00f6gren's syndrome. https:\/\/ClinicalTrials.gov\/show\/NCT03023592. Accessed 18 Jan 2017"},{"key":"762_CR119","unstructured":"NIH (2020) A Study of RoActemra\/Actemra (Tocilizumab) versus placebo in patients with systemic sclerosis. https:\/\/ClinicalTrials.gov\/show\/NCT01532869. Accessed 23 Sept 2016"},{"key":"762_CR120","unstructured":"NIH (2020) A study to evaluate safety and tolerability of multiple doses of MEDI-546 in adult subjects with scleroderma. https:\/\/ClinicalTrials.gov\/show\/NCT00930683. Accessed 8 May 2012"},{"key":"762_CR121","unstructured":"NIH (2020) A trial to compare nintedanib with placebo for patients with scleroderma related lung fibrosis. https:\/\/ClinicalTrials.gov\/show\/NCT02597933. Accessed 13 Dec 2019"},{"issue":"3","key":"762_CR122","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.molmed.2018.12.008","volume":"25","author":"LJ O\u2019Neil","year":"2019","unstructured":"O\u2019Neil LJ, Kaplan MJ (2019) Neutrophils in rheumatoid arthritis: breaking immune tolerance and fueling disease. Trends Mol Med 25(3):215\u2013227","journal-title":"Trends Mol Med"},{"issue":"1","key":"762_CR123","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jcph.185","volume":"54","author":"S Ohta","year":"2014","unstructured":"Ohta S, Tsuru T, Terao K, Mogi S, Suzaki M, Shono E et al (2014) Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). J Clin Pharmacol 54(1):109\u2013119","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"762_CR124","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s13075-016-1168-x","volume":"18","author":"M Okr\u00f3j","year":"2016","unstructured":"Okr\u00f3j M, Johansson M, Saxne T, Blom AM, Hesselstrand R (2016) Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis. Arthritis Res Ther 18(1):267\u2013267. https:\/\/doi.org\/10.1186\/s13075-016-1168-x","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"762_CR125","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1038\/cti.2016.26","volume":"5","author":"S Oon","year":"2016","unstructured":"Oon S, Wilson NJ, Wicks IJ (2016) Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Clin Transl Immunol 5(5):e79","journal-title":"Clin Transl Immunol"},{"issue":"9","key":"762_CR126","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1093\/rheumatology\/kes090","volume":"51","author":"S O'Reilly","year":"2012","unstructured":"O'Reilly S, Hugle T, van Laar JM (2012) T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford) 51(9):1540\u20131549. https:\/\/doi.org\/10.1093\/rheumatology\/kes090","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"762_CR127","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/imm.12260","volume":"143","author":"S O'Reilly","year":"2014","unstructured":"O'Reilly S, Cant R, Ciechomska M, Finnigan J, Oakley F, Hambleton S, van Laar JM (2014a) Serum amyloid A induces interleukin-6 in dermal fibroblasts via Toll-like receptor 2, interleukin-1 receptor-associated kinase 4 and nuclear factor-\u03baB. Immunology 143(3):331\u2013340. https:\/\/doi.org\/10.1111\/imm.12260","journal-title":"Immunology"},{"issue":"14","key":"762_CR128","doi-asserted-by":"publisher","first-page":"9952","DOI":"10.1074\/jbc.M113.545822","volume":"289","author":"S O'Reilly","year":"2014","unstructured":"O'Reilly S, Ciechomska M, Cant R, van Laar JM (2014b) Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-\u03b2 (TGF-\u03b2) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J Biol Chem 289(14):9952\u20139960. https:\/\/doi.org\/10.1074\/jbc.M113.545822","journal-title":"J Biol Chem"},{"issue":"3","key":"762_CR129","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2249.2009.04071.x","volume":"159","author":"Y Ozaki","year":"2010","unstructured":"Ozaki Y, Ito T, Son Y, Amuro H, Shimamoto K, Sugimoto H et al (2010) Decrease of blood dendritic cells and increase of tissue-infiltrating dendritic cells are involved in the induction of Sj\u00f6gren's syndrome but not in the maintenance. Clin Exp Immunol 159(3):315\u2013326","journal-title":"Clin Exp Immunol"},{"key":"762_CR130","doi-asserted-by":"crossref","first-page":"205031211987614","DOI":"10.1177\/2050312119876146","volume":"7","author":"MA Pab\u00f3n-Porras","year":"2019","unstructured":"Pab\u00f3n-Porras MA, Molina-R\u00edos S, Fl\u00f3rez-Su\u00e1rez JB, Coral-Alvarado PX, M\u00e9ndez-Patarroyo P, Quintana-L\u00f3pez G (2019) Rheumatoid arthritis and systemic lupus erythematosus: pathophysiological mechanisms related to innate immune system. SAGE Open Med 7:2050312119876146","journal-title":"SAGE Open Med"},{"issue":"12","key":"762_CR131","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1038\/jid.2011.224","volume":"131","author":"HF Pan","year":"2011","unstructured":"Pan HF, Wang J, Leng RX, Li XP, Ye DQ (2011) Interleukin-18: friend or foe for systemic sclerosis? J Invest Dermatol 131(12):2495. https:\/\/doi.org\/10.1038\/jid.2011.224 (author reply 2496-2497)","journal-title":"J Invest Dermatol"},{"issue":"2","key":"762_CR132","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1159\/000481609","volume":"43","author":"Q Pan","year":"2017","unstructured":"Pan Q, Feng Y, Peng Y, Zhou H, Deng Z, Li L et al (2017) Basophil recruitment to skin lesions of patients with systemic lupus erythematosus mediated by CCR1 and CCR2. Cell Physiol Biochem 43(2):832\u2013839","journal-title":"Cell Physiol Biochem"},{"key":"762_CR133","doi-asserted-by":"crossref","first-page":"429878","DOI":"10.1155\/2015\/429878","volume":"2015","author":"AB Paoliello-Paschoalato","year":"2015","unstructured":"Paoliello-Paschoalato AB, Marchi LF, Andrade MF, Kabeya LM, Donadi EA, Lucisano-Valim YM (2015) Fc\u03b3 and complement receptors and complement proteins in neutrophil activation in rheumatoid arthritis: contribution to pathogenesis and progression and modulation by natural products. Evidence-Based Complem Alternat Med eCAM 2015:429878","journal-title":"Evidence-Based Complem Alternat Med eCAM"},{"key":"762_CR134","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/OARRR.S167783","volume":"11","author":"SG Pasoto","year":"2019","unstructured":"Pasoto SG, de Oliveira Martins VA, Bonfa E (2019) Sj\u00f6gren\u2019s syndrome and systemic lupus erythematosus: links and risks. Open Access Rheumatol 11:33","journal-title":"Open Access Rheumatol"},{"key":"762_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00272","author":"D Pattanaik","year":"2015","unstructured":"Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE (2015) Pathogenesis of systemic sclerosis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2015.00272","journal-title":"Front Immunol"},{"issue":"1","key":"762_CR136","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41467-018-03129-8","volume":"9","author":"C Pellefigues","year":"2018","unstructured":"Pellefigues C, Dema B, Lamri Y, Saidoune F, Chavarot N, Loh\u00e9ac C et al (2018) Prostaglandin D 2 amplifies lupus disease through basophil accumulation in lymphoid organs. Nat Commun 9(1):725","journal-title":"Nat Commun"},{"issue":"133","key":"762_CR137","first-page":"191","volume":"24","author":"P Pentony","year":"2017","unstructured":"Pentony P, Duquenne L, Dutton K, Mankia K, Gul H, Vital E, Emery P (2017) The initiation of autoimmunity at epithelial surfaces: a focus on rheumatoid arthritis and systemic lupus erythematosus. Discov Med 24(133):191\u2013200","journal-title":"Discov Med"},{"key":"762_CR138","first-page":"1403","volume":"77","author":"C Pohlmeyer","year":"2018","unstructured":"Pohlmeyer C, Cui Z-H, Han P, Clarke A, Jones R, Mollova N et al (2018) AB0484 Monotherapy with filgotinib, a jak1-selective inhibitor, reduces disease severity and alters immune cell subsets in the nzb\/w f1 murine model of lupus. Ann Rheum Dis 77:1403","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"762_CR139","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrrheum.2017.107","volume":"13","author":"J Pozsgay","year":"2017","unstructured":"Pozsgay J, Szekanecz Z, S\u00e1rmay G (2017) Antigen-specific immunotherapies in rheumatic diseases. Nat Rev Rheumatol 13(9):525","journal-title":"Nat Rev Rheumatol"},{"key":"762_CR140","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.intimp.2018.10.016","volume":"65","author":"AK Rana","year":"2018","unstructured":"Rana AK, Li Y, Dang Q, Yang F (2018) Monocytes in rheumatoid arthritis: circulating precursors of macrophages and osteoclasts and their heterogeneity and plasticity role in RA pathogenesis. Int Immunopharmacol 65:348\u2013359","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"762_CR141","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1136\/annrheumdis-2018-213418","volume":"77","author":"F Rivellese","year":"2018","unstructured":"Rivellese F, Mauro D, Nerviani A, Pagani S, Fossati-Jimack L, Messemaker T et al (2018) Mast cells in early rheumatoid arthritis associate with disease severity and support B cell autoantibody production. Ann Rheum Dis 77(12):1773\u20131781","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"762_CR142","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.3390\/ijms20215435","volume":"20","author":"C Rizzo","year":"2019","unstructured":"Rizzo C, La Barbera L, Lo Pizzo M, Ciccia F, Sireci G, Guggino G (2019) Invariant NKT cells and rheumatic disease: focus on primary Sjogren syndrome. Int J Mol Sci 20(21):5435","journal-title":"Int J Mol Sci"},{"issue":"8","key":"762_CR143","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1471-4906(01)01955-X","volume":"22","author":"L Ronnblom","year":"2001","unstructured":"Ronnblom L, Alm GV (2001) An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 22(8):427\u2013431","journal-title":"Trends Immunol"},{"issue":"10","key":"762_CR144","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1084\/jem.20132620","volume":"211","author":"SL Rowland","year":"2014","unstructured":"Rowland SL, Riggs JM, Gilfillan S, Bugatti M, Vermi W, Kolbeck R et al (2014) Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model. J Exp Med 211(10):1977\u20131991","journal-title":"J Exp Med"},{"issue":"195","key":"762_CR145","doi-asserted-by":"crossref","first-page":"195ra196","DOI":"10.1126\/scitranslmed.3005727","volume":"5","author":"S Rusakiewicz","year":"2013","unstructured":"Rusakiewicz S, Nocturne G, Lazure T, Semeraro M, Flament C, Caillat-Zucman S et al (2013) NCR3\/NKp30 contributes to pathogenesis in primary Sj\u00f6gren\u2019s syndrome. Sci Transl Med 5(195):195ra196","journal-title":"Sci Transl Med"},{"issue":"1","key":"762_CR146","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/14712598.2017.1235698","volume":"17","author":"D Sambataro","year":"2017","unstructured":"Sambataro D, Sambataro G, Dal Bosco Y, Polosa RJ (2017) Present and future of biologic drugs in primary Sj\u00f6gren\u2019s syndrome. Expert Opin Biol Therapy 17(1):63\u201375","journal-title":"Expert Opin Biol Therapy"},{"issue":"3","key":"762_CR147","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1365-2249.2004.02642.x","volume":"138","author":"E Scala","year":"2004","unstructured":"Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F et al (2004) Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 138(3):540\u2013546. https:\/\/doi.org\/10.1111\/j.1365-2249.2004.02642.x","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"762_CR148","doi-asserted-by":"publisher","first-page":"e12162","DOI":"10.1371\/journal.pone.0012162","volume":"5","author":"C Scambi","year":"2010","unstructured":"Scambi C, La Verde V, De Franceschi L, Barausse G, Poli F, Benedetti F et al (2010) Comparative proteomic analysis of serum from patients with systemic sclerosis and sclerodermatous GVHD. Evidence of defective function of factor H. PLoS One 5(8):e12162. https:\/\/doi.org\/10.1371\/journal.pone.0012162","journal-title":"PLoS One"},{"issue":"6","key":"762_CR149","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/00002281-200011000-00002","volume":"12","author":"EA Shamim","year":"2000","unstructured":"Shamim EA, Rider LG, Miller FW (2000) Update on the genetics of the idiopathic inflammatory myopathies. Curr Opin Rheumatol 12(6):482\u2013491","journal-title":"Curr Opin Rheumatol"},{"key":"762_CR150","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4161\/mabs.12304","volume":"2","author":"DJ Shealy","year":"2010","unstructured":"Shealy DJ et al (2010) Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor \u03b1. mAbs 2:428\u2013439","journal-title":"mAbs"},{"key":"762_CR151","doi-asserted-by":"crossref","first-page":"4569826","DOI":"10.1155\/2019\/4569826","volume":"2019","author":"A Sierra-Sep\u00falveda","year":"2019","unstructured":"Sierra-Sep\u00falveda A, Esquinca-Gonz\u00e1lez A, Benavides-Su\u00e1rez SA, Sordo-Lima DE, Caballero-Islas AE, Cabral-Casta\u00f1eda AR, Rodr\u00edguez-Reyna TS (2019) Systemic sclerosis pathogenesis and emerging therapies, beyond the fibroblast. Biomed Res Int 2019:4569826","journal-title":"Biomed Res Int"},{"issue":"5","key":"762_CR152","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.yjmcc.2012.01.021","volume":"52","author":"MV Singh","year":"2012","unstructured":"Singh MV, Swaminathan PD, Luczak ED, Kutschke W, Weiss RM, Anderson ME (2012) MyD88 mediated inflammatory signaling leads to CaMKII oxidation, cardiac hypertrophy and death after myocardial infarction. J Mol Cell Cardiol 52(5):1135\u20131144. https:\/\/doi.org\/10.1016\/j.yjmcc.2012.01.021","journal-title":"J Mol Cell Cardiol"},{"issue":"1\u20133","key":"762_CR153","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12026-015-8705-6","volume":"63","author":"M Son","year":"2015","unstructured":"Son M, Diamond B, Santiago-Schwarz F (2015) Fundamental role of C1q in autoimmunity and inflammation. Immunol Res 63(1\u20133):101\u2013106","journal-title":"Immunol Res"},{"key":"762_CR154","first-page":"985753","volume":"2013","author":"L Sun","year":"2013","unstructured":"Sun L (2013) Roles of \u03b3 \u03b4 T Cells in the Pathogenesis of Autoimmune Diseases. Clin Dev Immunol 2013:985753","journal-title":"Clin Dev Immunol"},{"issue":"Suppl 2","key":"762_CR155","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1136\/annrheumdis-2017-eular.5799","volume":"76","author":"P Taylor","year":"2017","unstructured":"Taylor P, Westhovens R, Aa AV, Jamoul C, Li W, Goyal L et al (2017) THU0206 The jak1-selective inhibitor filgotinib reduces multiple markers of inflammation linked to various pathologic cell types and processes in rheumatoid arthritis patients. Ann Rheum Dis 76(Suppl 2):281\u2013282. https:\/\/doi.org\/10.1136\/annrheumdis-2017-eular.5799","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"762_CR156","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/annrheumdis-2012-eular.3140","volume":"71","author":"I Tcherepanova","year":"2013","unstructured":"Tcherepanova I, Curtis M, Sale M, Miesowicz F, Nicolette CJ (2013) SAT0193 Results of a randomized placebo controlled phase ia study of AGS-009, a humanized anti-interferon-\u03b1 monoclonal antibody in subjects with systemic lupus erythematosus. Ann Rheum Dis 71(Suppl 3):536\u2013537","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"762_CR157","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/bcp.12509","volume":"79","author":"D Ternant","year":"2015","unstructured":"Ternant D, Ducourau E, Fuzibet P, Vignault C, Watier H, Lequerr\u00e9 T et al (2015) Pharmacokinetics and concentration\u2013effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol 79(2):286\u2013297. https:\/\/doi.org\/10.1111\/bcp.12509","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"762_CR158","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00005072-199603000-00009","volume":"55","author":"DS Tews","year":"1996","unstructured":"Tews DS, Goebel HH (1996) Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 55(3):342\u2013347","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"762_CR159","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s002960050070","volume":"18","author":"M Tishler","year":"1999","unstructured":"Tishler M, Yaron I, Shirazi I, Yossipov Y, Yaron M (1999) Increased salivary interleukin-6 levels in patients with primary Sj\u00f6gren's syndrome. Rheumatol Int 18(4):125\u2013127","journal-title":"Rheumatol Int"},{"issue":"2","key":"762_CR160","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/art.33350","volume":"64","author":"A Tournadre","year":"2012","unstructured":"Tournadre A, Lenief V, Eljaafari A, Miossec P (2012) Immature muscle precursors are a source of interferon-\u03b2 in myositis: role of Toll-like receptor 3 activation and contribution to HLA class I up-regulation. Arthritis Rheum 64(2):533\u2013541. https:\/\/doi.org\/10.1002\/art.33350","journal-title":"Arthritis Rheum"},{"issue":"8","key":"762_CR161","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrrheum.2016.91","volume":"12","author":"IA Udalova","year":"2016","unstructured":"Udalova IA, Mantovani A, Feldmann M (2016) Macrophage heterogeneity in the context of rheumatoid arthritis. Nat Rev Rheumatol 12(8):472","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"762_CR162","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/art.20220","volume":"50","author":"A-K Ulfgren","year":"2004","unstructured":"Ulfgren A-K, Grundtman C, Borg K, Alexanderson H, Andersson U, Harris HE, Lundberg IE (2004) Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum 50(5):1586\u20131594. https:\/\/doi.org\/10.1002\/art.20220","journal-title":"Arthritis Rheum"},{"issue":"1","key":"762_CR163","doi-asserted-by":"crossref","first-page":"101485","DOI":"10.1016\/j.berh.2020.101485","volume":"34","author":"LL van den Hoogen","year":"2020","unstructured":"van den Hoogen LL, van Laar JM (2020) Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sj\u00f6gren's syndrome. Best Pract Res Clin Rheumatol 34(1):101485","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"762_CR164","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/03009740802572467","volume":"38","author":"AWT van Lieshout","year":"2009","unstructured":"van Lieshout AWT, Vonk MC, Bredie SJH, Joosten LBA, Netea MG, van Riel PLCM et al (2009) Enhanced interleukin-10 production by dendritic cells upon stimulation with Toll-like receptor 4 agonists in systemic sclerosis that is possibly implicated in CCL18 secretion. Scand J Rheumatol 38(4):282\u2013290. https:\/\/doi.org\/10.1080\/03009740802572467","journal-title":"Scand J Rheumatol"},{"issue":"10155","key":"762_CR165","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","volume":"392","author":"RF Van Vollenhoven","year":"2018","unstructured":"Van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z et al (2018) Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet 392(10155):1330\u20131339","journal-title":"Lancet"},{"issue":"3","key":"762_CR166","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-3083.2006.01811.x","volume":"64","author":"P Vogelsang","year":"2006","unstructured":"Vogelsang P, Jonsson M, Dalvin S, Appel S (2006) Role of dendritic cells in Sj\u00f6gren's syndrome. Scand J Immunol 64(3):219\u2013226","journal-title":"Scand J Immunol"},{"key":"762_CR167","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.intimp.2017.07.019","volume":"50","author":"Y Wang","year":"2017","unstructured":"Wang Y, Han C-C, Cui D, Li Y, Ma Y, Wei W (2017) Is macrophage polarization important in rheumatoid arthritis? Int Immunopharmacol 50:345\u2013352","journal-title":"Int Immunopharmacol"},{"key":"762_CR168","first-page":"947","volume-title":"Molecular and cellular mechanisms to the clinic","author":"ER Watts","year":"2018","unstructured":"Watts ER, Ryan E, Walmsley SR, Whyte MKB (2018) Microenvironmental regulation of innate immune cell function. In: Cavaillon JM, Singer M (eds) Molecular and cellular mechanisms to the clinic, 1st edn. Wiley-VCHVerlagGmbH&Co.KGaA, France, pp 947\u2013970","edition":"1"},{"issue":"11","key":"762_CR169","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/art.23989","volume":"58","author":"CA Wijbrandts","year":"2008","unstructured":"Wijbrandts CA, Remans PH, Klarenbeek PL, Wouters D, van den Bergh Weerman MA, Smeets TJ et al (2008) Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients. Arthritis Rheum 58(11):3330\u20133339","journal-title":"Arthritis Rheum"},{"issue":"3","key":"762_CR170","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.semarthrit.2008.04.002","volume":"39","author":"P Willeke","year":"2009","unstructured":"Willeke P, Schl\u00fcter B, Schotte H, Domschke W, Gaubitz M, Becker H (2009) Interferon-\u03b3 is increased in patients with primary Sjogren's syndrome and Raynaud's phenomenon. Semin Arthritis Rheum 39(3):197\u2013202","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"762_CR171","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.21729","volume":"54","author":"D Wouters","year":"2006","unstructured":"Wouters D, Voskuyl AE, Molenaar ET, Dijkmans BA, Hack CE (2006) Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q\u2013C4 complexes as novel activation products. Arthritis Rheum 54(4):1143\u20131150","journal-title":"Arthritis Rheum"},{"issue":"10","key":"762_CR172","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nrrheum.2014.80","volume":"10","author":"HL Wright","year":"2014","unstructured":"Wright HL, Moots RJ, Edwards SW (2014) The multifactorial role of neutrophils in rheumatoid arthritis. Nat Rev Rheumatol 10(10):593","journal-title":"Nat Rev Rheumatol"},{"key":"762_CR173","doi-asserted-by":"crossref","first-page":"246126","DOI":"10.1155\/2015\/246126","volume":"2015","author":"Y Xu","year":"2015","unstructured":"Xu Y, Chen G (2015) Mast cell and autoimmune diseases. Mediat Inflamm 2015:246126","journal-title":"Mediat Inflamm"},{"issue":"5","key":"762_CR174","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/ar3493","volume":"13","author":"K Yoshimoto","year":"2011","unstructured":"Yoshimoto K, Tanaka M, Kojima M, Setoyama Y, Kameda H, Suzuki K et al (2011) Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sj\u00f6gren's syndrome. Arthritis Res Ther 13(5):170","journal-title":"Arthritis Res Ther"},{"key":"762_CR175","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3389\/fimmu.2019.01395","volume":"10","author":"H Yoshitomi","year":"2019","unstructured":"Yoshitomi H (2019) Regulation of immune responses and chronic inflammation by fibroblast-like synoviocytes. Front Immunol 10:1395","journal-title":"Front Immunol"},{"issue":"7","key":"762_CR176","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00296-017-3671-z","volume":"37","author":"MB Yu","year":"2017","unstructured":"Yu MB, Langridge WH (2017) The function of myeloid dendritic cells in rheumatoid arthritis. Rheumatol Int 37(7):1043\u20131051","journal-title":"Rheumatol Int"},{"issue":"4","key":"762_CR177","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1155\/S0962935192000371","volume":"1","author":"O Zamir","year":"1992","unstructured":"Zamir O, Hasselgren PO, Higashiguchi T, Frederick JA, Fischer JE (1992) Tumour necrosis factor (TNF) and interleukin-1 (IL-1) induce muscle proteolysis through different mechanisms. Mediators Inflamm 1(4):247\u2013250. https:\/\/doi.org\/10.1155\/S0962935192000371","journal-title":"Mediators Inflamm"},{"issue":"4","key":"762_CR178","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s10753-014-9848-7","volume":"37","author":"L Zhang","year":"2014","unstructured":"Zhang L, Yan JW, Wang YJ, Wan YN, Wang BX, Tao JH et al (2014) Association of interleukin 1 family with systemic sclerosis. Inflammation 37(4):1213\u20131220. https:\/\/doi.org\/10.1007\/s10753-014-9848-7","journal-title":"Inflammation"},{"key":"762_CR179","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3389\/fimmu","volume":"10","author":"M Zouali","year":"2019","unstructured":"Zouali M, La Cava A (2019) Editorial: innate immunity pathways in autoimmune diseases. Front Immunol 10:1245. https:\/\/doi.org\/10.3389\/fimmu","journal-title":"Front Immunol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-020-00762-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-020-00762-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-020-00762-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T11:10:41Z","timestamp":1723720241000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-020-00762-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,2]]},"references-count":179,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["762"],"URL":"https:\/\/doi.org\/10.1007\/s10787-020-00762-y","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,2]]},"assertion":[{"value":"15 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}